# A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

> **NCT06780137** · PHASE1,PHASE2 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 262 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Gocatamig
- **BIOLOGICAL:** Ifinatamab Deruxtecan (I-DXd)
- **BIOLOGICAL:** Durvalumab

## Key facts

- **NCT ID:** NCT06780137
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-27
- **Primary completion:** 2029-08-31
- **Final completion:** 2030-01-17
- **Target enrollment:** 262 (ESTIMATED)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06780137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06780137, "A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06780137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*